The Board of Directors of Affymax, Inc. (OTCPK:AFFY) is reviewing its strategic options as a result of the termination of the collaboration with Takeda Pharmaceutical Company Limited (TSE:4502). Affymax and Takeda would terminate their Omontys product partnership in September. The firms would also withdraw their new drug application with the U.S. Food and Drug Administration.